With buprenorphine use on the rise it has become more important than ever for the forensic laboratory to be capable of analyzing for it. Described is the approach used by the Georgia Bureau of Investigation for the screening and confirmation of buprenorphine in whole blood by liquid chromatography-tandem mass spectrometry (LC -MS-MS), along with case reviews for the first 2 months of method implementation. Screening by LC-MS-MS is capable of identifying buprenorphine cases at concentrations as low as 1-2 mg/L. Confirmatory testing is performed on both indicatively screened samples and cases where buprenorphine is specifically requested. Confirmatory analysis by LC-MS-MS has a limit of detection and limit of quantitation of 0.75 mg/L with estimated uncertainties of 7.2% at 1 mg/L, 3.5% at 10 mg/L and 4.8% at 20 mg/L based on a 95% confidence interval, with the highest percent coefficient of variation being 3.7% for the 1 mg/L level. Since its implementation, the laboratory has reported out nine cases for buprenorphine. Seven of those cases were detected by the initial screen and two were identified by a specific request for buprenorphine. The cases' average concentration was 4.25 mg/L with a mode of 3.1 mg/L.
Introduction
Buprenorphine is a synthetic partial opioid agonist that comes in a transdermal version, an injectable version, and two sublingual formulations, one with buprenorphine being the only active ingredient and the other a combination of buprenorphine and naloxone to prevent patients from dissolving pills and injecting them (1, 2) . Available since 1985, buprenorphine has increased in use across the USA for its applications in pain management clinics and management of opioid withdrawal ( Figure 1 ) (3 -5) . Along with the increased lawful use, there has also been an increase in abuse to the point where it is now more likely than methadone to appear in law enforcement drug seizures tested by forensic laboratories in the USA (6, 7) . With a potency up to 40 times that of morphine and central nervous system-depressant properties that may cause drowsiness, dizziness, confusion, fatigue and blurred vision, the analysis in a forensic laboratory is essential (3, 8) . Buprenorphine's analysis to this point has primarily been focused in the urine, serum or plasma with some publications about its analysis in whole blood, the standard matrix for forensic applications (9) (10) (11) (12) (13) . With buprenorphine use on the rise and more requests coming into the laboratory for its testing, the Georgia Bureau of Investigation has developed a simple procedure for the general screening and confirmatory analysis of buprenorphine in whole blood using liquid chromatographytandem mass spectrometry (LC -MS-MS). In this paper, these processes are described along with a brief summary of case concentrations.
Materials and methods

Chemicals and reagents
Buprenorphine and buprenorphine-d4 were purchased from Cerilliant (Round Rock, TX, USA). Methanol (HPLC grade), acetic acid (A.C.S. plus), methylene chloride (HPLC grade), isopropanol (HPLC grade), ammonium hydroxide (A.C.S plus), potassium phosphate monobasic and formic acid (88% w/v) was purchased from Fisher Scientific (Pittsburgh, PA, USA). Ammonium formate (99þ%) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Negative blood was screened for drugs of abuse and therapeutic drugs prior to use. Mobile phase A was 0.1% formic acid and 15 mM ammonium formate in Fisher Optima grade water and mobile phase B was 0.1% formic acid and 15 mM ammonium formate in Fisher Optima grade methanol.
Sample preparation/analysis Cases that are received by the laboratory are screened by LC-MS-MS using methods described in previous literature (14 -16) . Briefly, 1 mL of whole blood is processed through a precipitation procedure that is then divided into two aliquots for screening. One aliquot receives a six-panel CEDIA w screen for benzodiazepines, barbiturates, opiates, amphetamines, cocaine and THC. The second aliquot receives an 130 drug panel screen using LC-MS-MS. Buprenorphine was added to this general LC-MS-MS screen, although it reaches only the threshold for triggering an enhanced product ion scan (EPI) producing a full mass spectrum at 1-2 mg/L. Initial LC-MS-MS screening of buprenorphine is accomplished by using a nonselective transition that has higher sensitivity to aid in identifying cases for confirmation testing; confirmation testing is done using a more selective transition to ensure the reliability of analysis (Table I ). The screening transition is considered nonselective due to the transition occasionally being trigged by an unidentifiable substance, which is distinguishable from buprenorphine by mass spectrum (Figure 2 ). The initial screen is sufficient to identify certain cases that come into the laboratory, in particular those of moderate to high concentrations. The confirmation testing subsequently described is further performed on the samples that show an indication of buprenorphine from the screen, or in cases where it is specifically requested for analysis by the submitting agency.
Confirmatory testing is conducted using solid-phase extraction where initially 2 mL of 0.1 M phosphate buffer is added to a 2 mL aliquot of blood followed by 20 mL (2 mg/L) of buprenorphine-d4. Next, samples are mixed and then centrifuged for 10 min at 2000 rpm. Samples are then applied to a UCT Clean Screen w DAU mixed-mode column that was preconditioned with 2 mL methanol, 2 mL deionized water and 1 mL 0.1 M phosphate buffer. Next, the column is washed with 3 mL deionized water, 3 mL 1 N acetic acid and 3 mL methanol. The column is subsequently air dried under vacuum for at least 10 min at 15 inches Hg, and the drug elution is performed using 3 mL of 80/20/2 methylene chloride/isopropanol/ammonium hydroxide. Finally, the eluent is evaporated to dryness and reconstituted in 100 mL of 1 : 1 mobile phase A/mobile phase B (17).
Instrumentation
Buprenorphine testing was performed on an Applied Biosystems QTRAP TM 3200 (Carlsbad, CA, USA), with electrospray ionization in positive mode. Chromatography was accomplished by injecting 20 mL of specimen on a MetaSil Basic RP (3 mm, 50 Â 2.0 mm) column at a temperature of 308C. Separation was achieved by gradient elution using mobile phase A (A) and mobile phase B (B) on a Perkin Elmer series 200 auto-sampler, micro-pumps and column oven (Waltham, MA, USA). The gradient conditions were initially 95% (A) and 5% (B) for 1 min decreasing to 5% (A) and 95% (B) at 17 min and resetting to the initial conditions for a final 2 min producing a total run time of 20 min. The retention time for buprenorphine using these settings was 10.8 min. Instrumental parameters for quantitative analysis were set for multiple reaction monitoring (MRM), and the parameters for qualitative analysis were set to perform an enhanced product ion scan (EPI) for full mass spectral identification to a library match internally generated by the Georgia Bureau of Investigation (Figure 2 ). Owing to an institutional requirement, two separate analyses of a compound for reporting, the qualitative and quantitative analyses are performed on two separate aliquots of sample.
Validation
Buprenorphine and buprenorphine-d4 were infused on the instrument to determine the optimal parameters (Table I) . Validation was performed by investigating limit of detection (LOD), limit of quantitation (LOQ), precision and accuracy, linearity, recovery, matrix effects, selectivity and stability.
LOD and LOQ
The LOD was established to be 0.75 mg/L; with the criteria that the method produce a qualitative full mass spectrum identification when compared with an internal library reference, and produce a signal-to-noise ratio of greater than 3 : 1. The LOQ was determined to be 0.75 mg/L, the concentration in which the signal-to-noise ratio proved to be greater than 10 : 1 for the MRM transition.
Precision and accuracy
The variability was determined for the lowest, middle and the highest point of a calibration curve that ranged from 1 to 20 mg/ L. The variability was estimated to be 7.2% at 1 mg/L, 3.5% at 10 mg/L and 4.8% at 20 mg/L based on a 95% confidence interval, with the highest percent coefficient of variation (%CV) being 3.7% for the 1 mg/L level. Variability and %CV were determined using a series of fortified control sample analyses (N ¼ 30).
Linearity A seven-point calibration curve with concentrations ranging from 1 to 20 mg/L was incorporated, and the coefficient of determination (r 2 ) was 0.997.
Recovery
Analyzing blood samples fortified at a concentration of 10 mg/L, the percent recovery ranged from 60 to 80% with an average of 69% recovery. Figure 3 . Post column infusion chromatogram using Q1 parent ion scan of injected blood sample, overlaid with buprenorphine and buprenorphine-d4 standard peak retention times.
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Matrix effects Investigation of ion suppression or enhancement by postcolumn infusion of buprenorphine provided visualization of the effect of interfering species on the ionization of buprenorphine. This displayed areas of the gradient affected by the matrix and demonstrated no real effect at the retention time that buprenorphine elutes off the column (Figure 3 ).
Selectivity
An interference study was performed to determine method specificity. A total of 64 drugs that included analytes of similar molecular weight, retention time and structure were analyzed under the screen and the confirmatory LC-MS-MS methods. No drugs were found to interfere with the burprenorphine transitions. While there is an unidentifiable peak that occasionally triggers the transition for buprenorphine in the general screen, it is capable of being distinguished from buprenorphine by mass spectrum as demonstrated by Figure 2 .
Stability
The stability of extracted calibrators and controls were investigated on the day of the extraction and after 7 days of storage at room temperature. There was a 10% average increase in internal standard response ranging from 1 to 18%, probably due to evaporation during storage. The quantitative values of the two analyses were found to be within 3%, indicating that the internal standard compensated for any changes in the sample over time.
Qualitative samples produced similar mass spectrums to those obtained from the original analysis.
Cases
Buprenorphine analysis over the 2 months of its implementation, December 2012 -January 2013, revealed nine cases that were reported by the Georgia Bureau of Investigation. The initial screen was capable of detecting seven of the nine cases, with two being detected by the submitting agencies request for analysis. The average result was 4.25 mg/L with a mode of 3.1 mg/L (calculations include one result that was lower than the lowest calibrator of 1 mg/L). All but one case had additional drugs present, and all have been driving under the influence cases (Table II) .
Conclusions
The described method has proven its capacity for the screening and confirmatory analysis of buprenorphine in whole blood, capable of detecting and quantitating buprenorphine as low as 0.75 mg/L. Confirmatory analysis has also proven to be precise and accurate showing estimated uncertainties to be 7.2% at 1 mg/L, 3.5% at 10 mg/L and 4.8% at 20 mg/L based on a 95% confidence interval, with the highest %CV being 3.7% for the 1 mg/L level. It has shown to have little matrix effects and average percent recoveries from whole blood of 69%.
Since the methods implementation, the Georgia Bureau of Investigation has seen nine cases in only a 2-month period of time. All but two of those cases were detected by the initial screen. With a combination of screen results and further testing of buprenorphine-requested samples, a large percent of the buprenophine cases that come into the laboratory should now be confirmed increasing the thoroughness of reports by the laboratory. 11-Nor-delta-9-tetrahydrocannabinol-9-carboxylic acid.
